Hemophilia Market Analysis By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction [ITI]Therapy, Gene Therapy), And Segment Forecasts to 2024

  • ID: 3822888
  • Report
  • 84 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Baxalta
  • Bayer Healthcare
  • Biogen
  • Chugai Pharmaceutical Co.
  • CSL Behring
  • Novo Nordisk
  • MORE
Global hemophilia market is expected to reach USD 15.2 billion by 2024, according to this new report. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.

The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.

As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2013,including Nigeria, Togo, Mali, Zambia, Mauritania, and others.

Competitive pricing strategy is a vital factor promoting market players’ growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.

Further Key Findings From the Study Suggest:

Hemophilia B is expected to grow at a rapid rate of over 6.0% during the forecast period. Higher emphasis on pipeline products with an extended half-life and increasing incidence of hemophilia B affected patients are expected to be the prominent growth factors.

On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50.0% by 2024. However, prophylaxis is expected to be the fastest growing segment because of the requirement for better control of bleeding episodes and growing financial assistance programs by healthcare providers and industry players.

For instance, Grifols has launched the “AlphaNine SD Copay Card” and “ALPHANATE Copay Program” for immediate enrollment in prophylaxis treatment by patients.

On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.

For instance, Novo Nordisk is working on N8-GP, CSL Behring is working on CSL689 rVIIa-FP, and Bayer is working on BAY 94-9027.These are expected to be commercially available around 2017/2018. This is expected to improve treatment over the forecast period thereby boosting growth.

Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations. Majority of their products that are awaiting FDA approval have extended therapeutic use in adults as well as children.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxalta
  • Bayer Healthcare
  • Biogen
  • Chugai Pharmaceutical Co.
  • CSL Behring
  • Novo Nordisk
  • MORE
1. Methodology And Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources

2. Executive Summary
2.1. Hemophilia: Industry Snapshot and Key Buying Criteria, 2015 - 2024

3. Hemophilia Industry Outlook
3.1. Market Segmentation
3.2. Market Size and Growth Prospects
3.3. Hemophilia: Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key Opportunities Prioritized
3.5. Industry Analysis: Porter's
3.6. Hemophilia Market PESTEL Analysis, 2015

4. Hemophilia Type Outlook
4.1. Hemophilia Market Share by Type, 2015 & 2024
4.2. Hemophilia A
4.2.1. Hemophilia A market estimates and forecasts, 2013 - 2024 (USD Million)
4.3. Hemophilia B
4.3.1. Hemophilia B market estimates and forecasts, 2013 - 2024 (USD Million)
4.4. Hemophilia C
4.4.1. Hemophilia C market estimates and forecasts, 2013 - 2024 (USD Million)
4.5. Others
4.5.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)

5. Hemophilia Treatment Outlook
5.1. Hemophilia Market Share by Treatment, 2015 & 2024
5.2. On-demand
5.2.1. On-demand based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)
5.3. Prophylaxis
5.3.1. Prophylaxis-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)

6. Hemophilia Therapy Outlook
6.1. Hemophilia Market Share by Therapy, 2015 & 2024
6.2. Recombinant Therapy
6.2.1. Recombinant therapy-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)
6.3. Immune Tolerance Induction (ITI) Therapy
6.3.1. ITI therapy-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)
6.4. Gene Therapy
6.4.1. Gene therapy-based hemophilia market estimates and forecasts, 2013 - 2024 (USD Million)

7. Hemophilia Regional Outlook
7.1. Hemophilia Market Share by Region, 2015 & 2024
7.2. North America
7.2.1. North America market estimates and forecasts, by type, 2013 - 2024 (USD Million)
7.2.2. North America market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
7.2.2.1. U.S. market estimates and forecasts
7.2.2.2. Canada market estimates and forecasts
7.3. Europe
7.3.1. Europe market estimates and forecasts, by type, 2013 - 2024 (USD Million)
7.3.2. Europe market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
7.3.2.1. UK market estimates and forecasts
7.3.2.2. Germany market estimates and forecasts
7.4. Asia-Pacific
7.4.1. Asia-Pacific market estimates and forecasts, by type, 2013 - 2024 (USD Million)
7.4.2. Asia-Pacific market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
7.4.2.1. Japan market estimates and forecasts
7.4.2.2. China market estimates and forecasts
7.5. Latin America
7.5.1. Latin America market estimates and forecasts, by type, 2013 - 2024 (USD Million)
7.5.2. Latin America market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
7.5.2.1. Brazil market estimates and forecasts
7.5.2.2. Mexico market estimates and forecasts
7.6. Middle East and Africa (MEA)
7.6.1. MEA market estimates and forecasts, by type, 2013 - 2024 (USD Million)
7.6.2. MEA market estimates and forecasts, by treatment, 2013 - 2024 (USD Million)
7.6.2.1. South Africa market estimates and forecasts
7.6.2.2. Saudi Arabia market estimates and forecasts

8. Competitive Landscape
8.1. Novo Nordisk
8.1.1. Company profile
8.1.2. Financial performance
8.1.3. Product portfolio
8.1.4. Strategic initiatives
8.2. Biogen
8.2.1. Company profile
8.2.2. Financial performance
8.2.3. Product portfolio
8.2.4. Strategic initiatives
8.3. Chugai Pharmaceutical Co.
8.3.1. Company profile
8.3.2. Financial performance
8.3.3. Product portfolio
8.3.4. Strategic initiatives
8.4. Bayer Healthcare
8.4.1. Company profile
8.4.2. Financial performance
8.4.3. Product portfolio
8.4.4. Strategic initiatives
8.5. Pfizer, Inc.
8.5.1. Company profile
8.5.2. Financial performance
8.5.3. Product portfolio
8.5.4. Strategic initiatives
8.6. Shire Plc.
8.6.1. Company profile
8.6.2. Financial performance
8.6.3. Product portfolio
8.6.4. Strategic initiatives
8.7. Baxalta
8.7.1. Company profile
8.7.2. Financial performance
8.7.3. Product portfolio
8.7.4. Strategic initiatives
8.8. CSL Behring
8.8.1. Company profile
8.8.2. Financial performance
8.8.3. Product portfolio
8.8.4. Strategic initiatives
8.9. Octopharma
8.9.1. Company profile
8.9.2. Financial performance
8.9.3. Product portfolio
8.9.4. Strategic initiatives

List of Tables

Table 1 Hemophilia market - Industry summary & key buying criteria
Table 2 Hemophilia market, by type, 2013 - 2024 (USD Million)
Table 3 Hemophilia market, by treatment, 2013 - 2024 (USD Million)
Table 4 Hemophilia market, by therapy, 2013 - 2024 (USD Million)
Table 5 Hemophilia market, by region, 2013 - 2024 (USD Million)
Table 6 Hemophilia market- Key market driver analysis
Table 7 Hemophilia market- Key market restraint analysis
Table 8 North America hemophilia market, by type 2013 - 2024 (USD Million)
Table 9 North America hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 10 North America hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 11 U.S. hemophilia market, by type 2013 - 2024 (USD Million)
Table 12 U.S. hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 13 U.S. hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 14 Canada hemophilia market, by type 2013 - 2024 (USD Million)
Table 15 Canada hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 16 Canada hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 17 Europe hemophilia market, by type 2013 - 2024 (USD Million)
Table 18 Europe hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 19 Europe hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 20 UK hemophilia market, by type 2013 - 2024 (USD Million)
Table 21 UK hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 22 UK hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 23 Germany hemophilia market, by type 2013 - 2024 (USD Million)
Table 24 Germany hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 25 Germany hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 26 Asia-Pacific hemophilia market, by type 2013 - 2024 (USD Million)
Table 27 Asia-Pacific hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 28 Asia-Pacific hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 29 Japan hemophilia market, by type 2013 - 2024 (USD Million)
Table 30 Japan hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 31 Japan hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 32 China hemophilia market, by type 2013 - 2024 (USD Million)
Table 33 China hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 34 China hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 35 Latin America hemophilia market, by type 2013 - 2024 (USD Million)
Table 36 Latin America hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 37 Latin America hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 38 Brazil hemophilia market, by type 2013 - 2024 (USD Million)
Table 39 Brazil hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 40 Brazil hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 41 Mexico hemophilia market, by type 2013 - 2024 (USD Million)
Table 42 Mexico hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 43 Mexico hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 44 MEA hemophilia market, by type 2013 - 2024 (USD Million)
Table 45 MEA hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 46 MEA hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 50 South Africa hemophilia market, by type 2013 - 2024 (USD Million)
Table 47 South Africa hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 48 South Africa hemophilia market, by therapy 2013 - 2024 (USD Million)
Table 49 Saudi Arabia hemophilia market, by type 2013 - 2024 (USD Million)
Table 50 Saudi Arabia hemophilia market, by treatment 2013 - 2024 (USD Million)
Table 51 Saudi Arabia hemophilia market, by therapy 2013 - 2024 (USD Million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Novo Nordisk
- Biogen
- Chugai Pharmaceutical Co.
- Bayer Healthcare
- Pfizer, Inc.
- Shire Plc.
- Baxalta
- CSL Behring
- Octopharma
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll